iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
5.95
-0.37 (-5.85%)
Mar 31, 2025, 1:19 PM EDT - Market open
iTeos Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for iTeos Therapeutics stock have an average target of 26, with a low estimate of 15 and a high estimate of 46. The average target predicts an increase of 336.97% from the current stock price of 5.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for iTeos Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $19 → $17 | Buy | Maintains | $19 → $17 | +185.71% | Mar 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $22 → $15 | Buy | Maintains | $22 → $15 | +152.10% | Mar 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +673.11% | Mar 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +252.94% | Jan 16, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $31 → $19 | Buy | Maintains | $31 → $19 | +219.33% | Dec 19, 2024 |
Financial Forecast
Revenue This Year
6.83M
from 35.00M
Decreased by -80.49%
Revenue Next Year
15.14M
from 6.83M
Increased by 121.70%
EPS This Year
-3.97
from -3.32
EPS Next Year
-4.19
from -3.97
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.9M | 35.4M | 288.1M | ||
| Avg | 6.8M | 15.1M | 117.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.0% | 418.9% | 1,803.2% | ||
| Avg | -80.5% | 121.7% | 679.1% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.79 | -3.42 | -3.63 | ||
| Avg | -3.97 | -4.19 | -3.97 | ||
| Low | -5.72 | -5.57 | -4.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.